Context Therapeutics Inc. (CNTX) stock
CNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.18−0.02 (-8.69%)
Close on Nov 13, 2026Market cap $16.61MP/E –Yield –
Context Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Context Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$46.05M. For fiscal 2025 it was -$39.69M. The highest annual figure on record is -$10.53M in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$39.69M | – |
| FY2024 | Dec 31, 2024 | -$29.91M | – |
| FY2023 | Dec 31, 2023 | -$25.06M | – |
| FY2022 | Dec 31, 2022 | -$15.37M | – |
| FY2021 | Dec 31, 2021 | -$10.53M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$7.95M | – |
| Q2 FY2026 | Jun 30, 2026 | -$14.96M | – |
| Q1 FY2026 | Mar 31, 2026 | -$9.34M | – |
| Q4 FY2025 | Dec 31, 2025 | -$13.80M | – |
| Q3 FY2025 | Sep 30, 2025 | -$10.61M | – |
| Q2 FY2025 | Jun 30, 2025 | -$9.75M | – |
| Q1 FY2025 | Mar 31, 2025 | -$5.53M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.31M | – |
| Q3 FY2024 | Sep 30, 2024 | -$18.70M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.09M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.82M | – |
| Q4 FY2023 | Dec 31, 2023 | -$6.93M | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.18M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.29M | – |
| Q1 FY2023 | Mar 31, 2023 | -$6.66M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.88M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.04M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.00M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.44M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.09M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.57M | – |
See a number that looks wrong?